Vexev raises $6M to bring robotic vascular scanner to the US
What's the deal? Australian medical robotics company VexevDealroom has a profile for this one. Try Dealroom → has raised $6 million in early-stage funding to speed FDA 510(k) clearance and U.S. commercialization of VxWave, its robotic ultrasound platform for vascular imaging. The round brings total funding to date to $19 million.
What's the endgame? VxWave combines robotics, artificial intelligence, and ultrasound to automate vascular ultrasound scans. Vexev is developing it for upper-limb imaging, starting with dialysis vascular access, where patients need frequent monitoring.
Why now? The raise follows a multi-site clinical study with U.S. Renal CareDealroom has a profile for this one. Try Dealroom →, one of the country's largest dialysis providers. VxWave achieved a 94% scanning success rate when operated by non-specialist staff.
Cardiovascular disease is the world's leading cause of death, claiming nearly 20 million lives each year, yet access to quality vascular imaging remains limited by specialist availability.
Who's backing it? Existing investors Blackbird Ventures, Neotribe VenturesDealroom has a profile for this one. Try Dealroom →, StartmateDealroom has a profile for this one. Try Dealroom →, and HorizonDealroom has a profile for this one. Try Dealroom → joined new backers TEN13Dealroom has a profile for this one. Try Dealroom →, Bioshore VenturesDealroom has a profile for this one. Try Dealroom →, and Alumni Ventures. The money will fund regulatory work, manufacturing scale-up, and commercialization.
"We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available," said John Carroll, co-founder and chief executive officer of Vexev. The company plans to expand into cardiovascular and peripheral artery disease applications.
The signal: At $6 million, the round sits in the bottom half of comparable early-stage deals — a modest cheque for a company chasing a large clinical need. The bet is that autonomous imaging can ease a bottleneck that keeps quality scans tied to scarce specialists.
Read more: PR Newswire
Image credit: Vexev
